Anti-Tau [pS199](polyclonal)

Room temperature

12 months at -20°C
1 month at 4°C

Peptide

Obtained by immunizing a rabbit with a 12 amino acid peptide containing the phosphorylated serine 199 (SGYSSPGSPGT). The phosphorylated threonine is underlined.

Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D and Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 9(4):397-405.
Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E , Schraen-Maschke S, and Buee L (2008) Biochemistry of Tau in Alzheimer’s disease and related neurological disorders. Expert review of proteomics 5: 207–224.
Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Evrard C, Le Fur N, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Blum D, Hamdane M, Buée L, Melnyk P. New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer’s disease. Neurobiol Dis. 2019 Sep; 129:217-233.